Ergosta-7,9(11),22-trien-3 beta-ol Alleviates Intracerebral Hemorrhage-Induced Brain Injury and BV-2 Microglial Activation

doi:10.3390/molecules26102970

CSMUIR > researcher portal > Artical > Item 310902500/23718

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/23718

Title:	Ergosta-7,9(11),22-trien-3 beta-ol Alleviates Intracerebral Hemorrhage-Induced Brain Injury and BV-2 Microglial Activation
Authors:	Hsueh, PJ;Wang, MH;Hsiao, CJ;Chen, CK;Lin, FL;Huang, SH;Yen, JL;Tsai, PH;Kuo, YH;Hsiao, G
Keywords:	ergosta-7,9(11),22-trien-3 beta-ol;intracerebral hemorrhage;COX-2;MMP-9;microglia;JNK
Date:	2021
Issue Date:	2022-08-05T09:41:46Z (UTC)
Publisher:	MDPI
Abstract:	Intracerebral hemorrhage (ICH) is a devastating neurological disorder characterized by an exacerbation of neuroinflammation and neuronal injury, for which few effective therapies are available at present. Inhibition of excessive neuroglial activation has been reported to alleviate ICH-related brain injuries. In the present study, the anti-ICH activity and microglial mechanism of ergosta-7,9(11),22-trien-3 beta-ol (EK100), a bioactive ingredient from Asian medicinal herb Antrodia camphorate, were evaluated. Post-treatment of EK100 significantly attenuated neurobehavioral deficit and MRI-related brain lesion in the mice model of collagenase-induced ICH. Additionally, EK100 alleviated the inducible expression of cyclooxygenase (COX)-2 and the activity of matrix metalloproteinase (MMP)-9 in the ipsilateral brain regions. Consistently, it was shown that EK100 concentration-dependently inhibited the expression of COX-2 protein in Toll-like receptor (TLR)-4 activator lipopolysaccharide (LPS)-activated microglial BV-2 and primary microglial cells. Furthermore, the production of microglial prostaglandin E-2 and reactive oxygen species were attenuated by EK100. EK100 also attenuated the induction of astrocytic MMP-9 activation. Among several signaling pathways, EK100 significantly and concentration-dependently inhibited activation of c-Jun N-terminal kinase (JNK) MAPK in LPS-activated microglial BV-2 cells. Consistently, ipsilateral JNK activation was markedly inhibited by post-ICH-treated EK100 in vivo. In conclusion, EK100 exerted the inhibitory actions on microglial JNK activation, and attenuated brain COX-2 expression, MMP-9 activation, and brain injuries in the mice ICH model. Thus, EK100 may be proposed and employed as a potential therapeutic agent for ICH.
URI:	http://dx.doi.org/10.3390/molecules26102970 https://www.webofscience.com/wos/woscc/full-record/WOS:000655200400001 https://ir.csmu.edu.tw:8080/handle/310902500/23718
Relation:	MOLECULES ,2021,v26,issue 10
Appears in Collections:	[researcher portal] Artical

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	157	View/Open

Loading...